Table 1.
Baseline characteristics.
| Variables | Neovascular AMD (N = 517) |
|---|---|
| Age, years (IQR) | 71.4 (65–78, median 72) |
| Sex, n (%) | |
| Male | 311 (60) |
| Female | 206 (40) |
| Eye treated, n (%) | |
| Right | 272 (53) |
| Left | 245 (47) |
| Underlying disease, n (%) | |
| Hypertension | 245 (46) |
| Diabetes | 107 (21) |
| Subtypes of wet AMD, n (%) | |
| PCV | 167 (32) |
| Type 1 MNV, except PCV | 110 (22) |
| Type 2 MNV | 178 (34) |
| RAP (type 3 MNV) | 62 (12) |
| Treatment response, n (%)* | |
| Dry macula | 409 (79) |
| SRF remained | 85 (16) |
| IRF remained | 23 (5) |
| Visual acuity (logMAR, IQR)† | |
| Pre-injection | 0.43 (0.15–0.52, median 0.30) |
| 1-month after first injection | 0.36 (0.10–0.52, median 0.30) |
| 1-month after second injection | 0.31 (0.10–0.40, median 0.22) |
| 1-month after third injection | 0.29 (0.10–0.40, median 0.22) |
AMD age-related macular degeneration, IQR interquartile range, PCV polypoidal choroidal vasculopathy, MNV macular neovascularization, RAP retinal angiomatous proliferation, SRF subretinal fluid, IRF intraretinal fluid, logMAR logarithm of the minimum angle of resolution.
*After administering injections three monthly injections, the evaluation was conducted one month after the last injection using OCT (optical coherence tomography).
†Only the 203 individuals for whom visual acuity data could be obtained were listed.